Synosia Licenses Rufinamide From Novartis In Anxiety, Bipolar Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
The sodium channel blocker could have advantages over selective serotonin reuptake inhibitors, CEO tells “The Pink Sheet” DAILY.
You may also be interested in...
Synosia Will Initiate Phase II Studies Of Rufinamide In Anxiety, Bipolar Disorders In March
Company will evaluate 500 mg and 1 gm doses of the drug, after assessing three different doses in a proof-of-concept study.
Synosia Will Initiate Phase II Studies Of Rufinamide In Anxiety, Bipolar Disorders In March
Company will evaluate 500 mg and 1 gm doses of the drug, after assessing three different doses in a proof-of-concept study.
Roche Deal Gives Synosis A Leg Up In Central Nervous System Space
The newly launched company will develop five discontinued Roche central nervous system drug candidates.